PMID- 32535588
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1421-9794 (Electronic)
IS  - 0009-3157 (Linking)
VI  - 65
IP  - 1-2
DP  - 2020
TI  - Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy 
      for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based 
      on Randomized Controlled Trials.
PG  - 11-20
LID - 10.1159/000506671 [doi]
AB  - BACKGROUND: Platinum/S-1 (PS) and platinum/5-fluorouracil (PF) as first-line 
      chemotherapies are extensively used for the treatment of advanced gastric or 
      gastroesophageal junction cancer (AGC); however, there is no definite consensus 
      on which regimen is best. In our meta-analysis, we compared PS with PF in terms 
      of their efficacy and safety in AGC patients. METHODS: PubMed, ScienceDirect, Web 
      of Science, Scopus, Ovid MEDLINE, EMBASE, The Cochrane Library, Google Scholar, 
      and CNKI were systematically searched for pertinent literature. We analyzed 
      overall survival (OS), progression-free survival (PFS), objective response rate 
      (ORR), disease control rate (DCR), and adverse effects (AEs) as major end points. 
      RESULTS: A total of 3,225 studies were identified, among which 6 randomized 
      controlled trials, including 1,736 participants, were ultimately included in our 
      analysis. Our results showed that PS and PF were comparable in terms of OS (p = 
      0.33, 95% confidence interval [CI]: 0.84-1.06), PFS (p = 0.63, 95% CI: 
      0.87-1.09), ORR (p = 0.38, 95% CI: 0.91-1.28), DCR (p = 0.41, 95% CI: 0.86-1.43), 
      total AEs (p = 0.41, 95% CI: 0.98-1.01), and grade >/=3 AEs (p = 0.58, 95% CI: 
      0.82-1.41). However, those who received PF had a shorter time to failure (TTF) (p 
      = 0.01, 95% CI: 0.77-0.97), and a significantly higher rate and more severe cases 
      of stomatitis, nausea, and hypokalemia were reported in the PF group. 
      CONCLUSIONS: PF and PS show similar antitumor efficacy (OS, PFS, ORR, and DCR), 
      but patients receiving PS exhibit longer TTF and fewer AEs (stomatitis, nausea, 
      and hypokalemia) than those receiving PF.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Luo, Dongyi
AU  - Luo D
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Wang, Li
AU  - Wang L
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
AD  - Department of Digestive Oncology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Chen, Xinling
AU  - Chen X
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
AD  - Department of Digestive Oncology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Xiong, Yiting
AU  - Xiong Y
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Yi, Fengming
AU  - Yi F
AD  - Department of Digestive Oncology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Ding, Jingli
AU  - Ding J
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Ding, Hao
AU  - Ding H
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China, weiyip2000@hotmail.com.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200612
PL  - Switzerland
TA  - Chemotherapy
JT  - Chemotherapy
JID - 0144731
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Coordination Complexes)
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 49DFR088MY (Platinum)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Coordination Complexes/adverse effects/chemistry/*therapeutic use
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Esophagogastric Junction/pathology
MH  - Fluorouracil/adverse effects/*therapeutic use
MH  - Gastrointestinal Neoplasms/*drug therapy/mortality/pathology
MH  - Humans
MH  - Neoplasm Staging
MH  - Oxonic Acid/adverse effects/*therapeutic use
MH  - Platinum/chemistry
MH  - Proportional Hazards Models
MH  - Randomized Controlled Trials as Topic
MH  - Stomach Neoplasms/*drug therapy/mortality/pathology
MH  - Survival Analysis
MH  - Tegafur/adverse effects/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - 5-Fluorouracil
OT  - Advanced gastric cancer
OT  - Cisplatin
OT  - Meta-analysis
OT  - Oxaliplatin
OT  - Platinum
EDAT- 2020/06/15 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/02/20 00:00 [accepted]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 000506671 [pii]
AID - 10.1159/000506671 [doi]
PST - ppublish
SO  - Chemotherapy. 2020;65(1-2):11-20. doi: 10.1159/000506671. Epub 2020 Jun 12.